CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals today announced the appointment of Dr. Craig T. Basson, M.D., Ph.D., as Chief Medical Officer. Previously, Dr. Basson was Global Head of Translational Medicine (Cardiovascular and Metabolism) at Novartis for 10 years, where he led the team developing new global programs to translate basic findings into novel therapeutics.
“As a highly-regarded scientist and drug developer, Craig’s experience in global translational medicine is uniquely suited to Boston Pharmaceuticals as we continue to evolve our pipeline,” said Robert Armstrong, Ph.D., Chief Executive Officer and Co-Founder of Boston Pharmaceuticals. “His proven track record for innovation and drug development will support our mission of addressing unmet medical needs for larger patient populations.”
“Boston Pharmaceuticals’ strategy of following the data and selectively advancing a portfolio of high value candidates into differentiated therapeutics excites me,” said Dr. Basson. “I am thrilled to join Boston Pharmaceuticals at this time of important growth for the company and look forward to leveraging my experience to accelerate the development of the pipeline and to continuing to bring novel medicines to patients in need.”
Dr. Basson was previously Global Head of Translational Medicine for the Cardiovascular and Metabolic Therapeutic Areas at Novartis Institutes for Biomedical Research. At Novartis, he co-led the Cardiovascular Metabolism (CVM) Disease Area Decision Board, oversaw the leadership of early clinical portfolio through Proof of Concept (PoC) and supported late phase clinical programs by indication expansion PoC studies and specialized clinical pharmacology and profiling studies. He has been involved in the development of a number of important and novel medicines for patients with cardiovascular disease, diabetes, and metabolic disorders.
Prior to Novartis, Dr. Basson was a Professor of Cardiology and Internal Medicine at Cornell University Medical College. He obtained an M.Sc. in Physiological Sciences at the University of Oxford and completed an M.D. and Ph.D. at Yale University. Dr. Basson serves as a scientific advisor to various for-profit and non-profit organizations.
About Boston Pharmaceuticals
Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates. We employ unencumbered decision making, follow the data and advance only those programs that meet our stringent development hurdles. Following clinical proof of concept, we establish value creating partnerships with the world’s leading biotechnology and pharmaceutical companies or advance programs through commercialization. We are continuously seeking new opportunities to leverage our model to create a path to value for our partners and patients. For more information, please visit www.bostonpharmaceuticals.com.
